{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:22:51Z","timestamp":1779196971273,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006022","name":"French Government Ministry of Social Affairs Health and Womens Rights","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ijrobp.2022.09.069","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T22:08:37Z","timestamp":1664230117000},"page":"677-685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg\/m\u00b2) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-6347","authenticated-orcid":false,"given":"Axel","family":"Cailleteau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Maingon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9mi","family":"Bourdais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Lioure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Batard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Llagostera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine","family":"Guimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Andr\u00e9","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.09.069_bib0001","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0003","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00277-019-03663-5","article-title":"Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma","volume":"98","author":"Blanes","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du My\u00e9lome (IFM)","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0005","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0006","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/0360-3016(83)90412-1","article-title":"Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants","volume":"9","author":"Shank","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0007","first-page":"343","article-title":"Total body irradiation with or without lung shielding for allogeneic bone marrow transplantation","volume":"9","author":"Labar","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0008","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1702167","volume":"25","author":"Desikan","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0009","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2002-03-0889","article-title":"Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study","volume":"101","author":"Segeren","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0010","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0011","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1016\/j.transproceed.2013.03.054","article-title":"Continuous infusion cyclophosphamide and low-dose total body irradiation is a safe and effective conditioning regimen for autologous transplant in multiple myeloma","volume":"45","author":"Byrne","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0012","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1078-0432.CCR-10-1912","article-title":"Total marrow irradiation: A new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma","volume":"17","author":"Somlo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0013","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbmt.2005.10.026","article-title":"Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: An alternative to standard total body irradiation","volume":"12","author":"Wong","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0014","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.ijrobp.2006.10.047","article-title":"Image-guided total marrow and total lymphatic irradiation using helical tomotherapy","volume":"67","author":"Schultheiss","year":"2007","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.radonc.2019.07.010","article-title":"Multi-institutional evaluation of MVCT guided patient registration and dosimetric precision in total marrow irradiation: A global health initiative by the International Consortium of Total Marrow Irradiation","volume":"141","author":"Zuro","year":"2019","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0016","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00066-021-01769-2","article-title":"Total body irradiation of bone marrow transplant using helical tomotherapy with a focus on the quality of dose contribution at junction target volumes","volume":"197","author":"Sresty","year":"2021","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0017","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1080\/10428194.2017.1390231","article-title":"A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg\/m2 and total marrow irradiation (TMI) in patients with relapsed\/refractory multiple myeloma","volume":"59","author":"Patel","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0018","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41409-020-01181-x","article-title":"Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma","volume":"56","author":"Giebel","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0019","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00066-006-1528-6","article-title":"Biologically effective dose in total-body irradiation and hematopoietic stem cell transplantation","volume":"182","author":"Kal","year":"2006","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0020","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0021","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0022","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/ejh.12890","article-title":"Long-term follow-up of patients with multiple myeloma treated with total body irradiation-melphalan conditioning","volume":"99","author":"Munker","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0023","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0360-3016(96)85011-5","article-title":"Cataractogenesis after total body irradiation","volume":"35","author":"Belkac\u00e9mi","year":"1996","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0024","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2019.08.010","article-title":"Radiation-related toxicities using organ sparing total marrow irradiation transplant conditioning regimens","volume":"105","author":"Shinde","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0025","first-page":"1","article-title":"Total marrow irradiation as part of autologous stem cell transplantation for Asian patients with multiple myeloma","volume":"2013","author":"Lin","year":"2013","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0026","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: state of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0027","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0360-3016(00)01373-0","article-title":"Long-term complications of total body irradiation in adults","volume":"49","author":"Thomas","year":"2001","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0028","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2018-08-825349","article-title":"Pros and cons of frontline autologous transplant in multiple myeloma: The debate over timing","volume":"133","author":"Kumar","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0029","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0030","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): A randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0031","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-119762","article-title":"Subgroup analyses of the randomized GMMG phase III multicenter trial relapse suggest survival benefit of salvage autologous transplant primarily in low risk multiple myeloma","volume":"132","author":"Baertsch","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0032","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijrobp.2014.09.014","article-title":"Multi-institutional feasibility study of a fast patient localization method in total marrow irradiation with helical tomotherapy: A global health initiative by the International Consortium of Total Marrow Irradiation","volume":"91","author":"Takahashi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0033","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1748-717X-9-34","article-title":"Fast, simple, and informative patient-specific dose verification method for intensity modulated total marrow irradiation with helical tomotherapy","volume":"9","author":"Takahashi","year":"2014","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0034","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1016\/S1470-2045(20)30342-9","article-title":"Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia","volume":"21","author":"Wong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0035","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.3390\/cancers13174320","article-title":"Choosing the right therapy for patients with relapsed\/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors","volume":"13","author":"Gengenbach","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0036","series-title":"Update on Multiple Myeloma","first-page":"207","article-title":"Management of multiple myeloma in developing countries","author":"Collins Nwabuko","year":"2019"},{"key":"10.1016\/j.ijrobp.2022.09.069_bib0037","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in multiple myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transplant Cell Ther"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622033946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622033946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:04:53Z","timestamp":1759745093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622033946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0360301622033946"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.069","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg\/m\u00b2) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}